vs
KKR Real Estate Finance Trust Inc.（KREF）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
Xtant Medical Holdings, Inc.的季度营收约是KKR Real Estate Finance Trust Inc.的1.3倍（$32.4M vs $25.8M），Xtant Medical Holdings, Inc.净利率更高（0.2% vs -101.7%，领先101.9%），Xtant Medical Holdings, Inc.同比增速更快（2.7% vs -26.6%），过去两年Xtant Medical Holdings, Inc.的营收复合增速更高（7.7% vs -18.8%）
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
KREF vs XTNT — 直观对比
营收规模更大
XTNT
是对方的1.3倍
$25.8M
营收增速更快
XTNT
高出29.3%
-26.6%
净利率更高
XTNT
高出101.9%
-101.7%
两年增速更快
XTNT
近两年复合增速
-18.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $32.4M |
| 净利润 | $-26.2M | $57.0K |
| 毛利率 | — | 54.9% |
| 营业利润率 | -105.1% | -2.9% |
| 净利率 | -101.7% | 0.2% |
| 营收同比 | -26.6% | 2.7% |
| 净利润同比 | -229.6% | 101.8% |
| 每股收益（稀释后） | $-0.49 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KREFXTNT
| Q4 25 | $25.8M | $32.4M | ||
| Q3 25 | $25.3M | $33.3M | ||
| Q2 25 | $30.2M | $35.4M | ||
| Q1 25 | $31.3M | $32.9M | ||
| Q4 24 | $35.1M | $31.5M | ||
| Q3 24 | $37.0M | $27.9M | ||
| Q2 24 | $40.4M | $29.9M | ||
| Q1 24 | $39.1M | $27.9M |
净利润KREFXTNT
| Q4 25 | $-26.2M | $57.0K | ||
| Q3 25 | $13.8M | $1.3M | ||
| Q2 25 | $-29.7M | $3.5M | ||
| Q1 25 | $-4.9M | $58.0K | ||
| Q4 24 | $20.3M | $-3.2M | ||
| Q3 24 | $-7.4M | $-5.0M | ||
| Q2 24 | $25.8M | $-3.9M | ||
| Q1 24 | $-3.1M | $-4.4M |
毛利率KREFXTNT
| Q4 25 | — | 54.9% | ||
| Q3 25 | — | 66.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | — | 62.1% | ||
| Q1 24 | — | 62.1% |
营业利润率KREFXTNT
| Q4 25 | -105.1% | -2.9% | ||
| Q3 25 | 50.4% | 7.6% | ||
| Q2 25 | -101.3% | 13.1% | ||
| Q1 25 | -18.3% | 3.2% | ||
| Q4 24 | 55.8% | -6.0% | ||
| Q3 24 | -19.6% | -13.5% | ||
| Q2 24 | 63.3% | -9.8% | ||
| Q1 24 | -8.7% | -12.4% |
净利率KREFXTNT
| Q4 25 | -101.7% | 0.2% | ||
| Q3 25 | 54.4% | 3.9% | ||
| Q2 25 | -98.5% | 10.0% | ||
| Q1 25 | -15.5% | 0.2% | ||
| Q4 24 | 57.7% | -10.0% | ||
| Q3 24 | -20.0% | -18.0% | ||
| Q2 24 | 63.9% | -12.9% | ||
| Q1 24 | -7.9% | -15.8% |
每股收益（稀释后）KREFXTNT
| Q4 25 | $-0.49 | $0.00 | ||
| Q3 25 | $0.12 | $0.01 | ||
| Q2 25 | $-0.53 | $0.02 | ||
| Q1 25 | $-0.15 | $0.00 | ||
| Q4 24 | $0.22 | $-0.02 | ||
| Q3 24 | $-0.19 | $-0.04 | ||
| Q2 24 | $0.29 | $-0.03 | ||
| Q1 24 | $-0.13 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.6M | $17.1M |
| 总债务越低越好 | — | $11.0M |
| 股东权益账面价值 | $1.2B | $51.0M |
| 总资产 | $6.5B | $94.1M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资KREFXTNT
| Q4 25 | $84.6M | $17.1M | ||
| Q3 25 | $204.1M | $10.4M | ||
| Q2 25 | $107.7M | $6.9M | ||
| Q1 25 | $106.4M | $5.0M | ||
| Q4 24 | $104.9M | $6.2M | ||
| Q3 24 | $108.8M | $6.6M | ||
| Q2 24 | $107.2M | $5.4M | ||
| Q1 24 | $106.5M | $4.5M |
总债务KREFXTNT
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益KREFXTNT
| Q4 25 | $1.2B | $51.0M | ||
| Q3 25 | $1.2B | $50.4M | ||
| Q2 25 | $1.2B | $48.5M | ||
| Q1 25 | $1.3B | $43.9M | ||
| Q4 24 | $1.3B | $43.0M | ||
| Q3 24 | $1.4B | $45.7M | ||
| Q2 24 | $1.4B | $45.0M | ||
| Q1 24 | $1.4B | $47.7M |
总资产KREFXTNT
| Q4 25 | $6.5B | $94.1M | ||
| Q3 25 | $6.5B | $106.3M | ||
| Q2 25 | $6.8B | $103.5M | ||
| Q1 25 | $6.6B | $95.8M | ||
| Q4 24 | $6.4B | $93.8M | ||
| Q3 24 | $6.8B | $98.9M | ||
| Q2 24 | $7.1B | $95.6M | ||
| Q1 24 | $7.3B | $93.9M |
负债/权益比KREFXTNT
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | — | $5.0M |
| 自由现金流率自由现金流/营收 | — | 15.4% |
| 资本支出强度资本支出/营收 | — | 1.2% |
| 现金转化率经营现金流/净利润 | — | 94.39× |
| 过去12个月自由现金流最近4个季度 | — | $10.2M |
8季度趋势，按日历期对齐
经营现金流KREFXTNT
| Q4 25 | $72.3M | $5.4M | ||
| Q3 25 | $18.5M | $4.6M | ||
| Q2 25 | $21.1M | $1.3M | ||
| Q1 25 | $15.9M | $1.3M | ||
| Q4 24 | $132.6M | $665.0K | ||
| Q3 24 | $49.1M | $-1.7M | ||
| Q2 24 | $30.6M | $-5.1M | ||
| Q1 24 | $34.5M | $-5.8M |
自由现金流KREFXTNT
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $910.0K | ||
| Q1 25 | — | $87.0K | ||
| Q4 24 | — | $-7.0K | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $-5.7M | ||
| Q1 24 | — | $-6.5M |
自由现金流率KREFXTNT
| Q4 25 | — | 15.4% | ||
| Q3 25 | — | 12.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | -0.0% | ||
| Q3 24 | — | -13.7% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -23.4% |
资本支出强度KREFXTNT
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.8% |
现金转化率KREFXTNT
| Q4 25 | — | 94.39× | ||
| Q3 25 | 1.34× | 3.53× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 22.03× | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KREF
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
